602 filings
Page 4 of 31
10-K
2022 FY
DARE
Dare Bioscience Inc
Annual report
30 Mar 23
4:02pm
8-K
DARE
Dare Bioscience Inc
30 Mar 23
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
8:05am
8-K
DARE
Dare Bioscience Inc
13 Mar 23
Other Events
8:20am
8-K
DARE
Dare Bioscience Inc
6 Feb 23
Other Events
8:00am
8-K
DARE
Dare Bioscience Inc
27 Jan 23
Amendments to Articles of Incorporation or Bylaws
5:15pm
4
DARE
Dare Bioscience Inc
26 Jan 23
Dare Bioscience / SABRINA MARTUCCI JOHNSON ownership change
4:07pm
4
Walters-Hoffert Lisa
26 Jan 23
Dare Bioscience / Lisa Walters-Hoffert ownership change
4:06pm
4
DARE
Dare Bioscience Inc
26 Jan 23
Dare Bioscience / John A Fair ownership change
4:05pm
8-K
DARE
Dare Bioscience Inc
25 Jan 23
Other Events
8:00am
8-K
DARE
Dare Bioscience Inc
9 Jan 23
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
8:05am
8-K
DARE
Dare Bioscience Inc
16 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:10pm
8-K
DARE
Dare Bioscience Inc
12 Dec 22
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
8:05am
8-K
DARE
Dare Bioscience Inc
5 Dec 22
Other Events
7:45am
8-K
DARE
Dare Bioscience Inc
14 Nov 22
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
8:05am
10-Q
2022 Q3
DARE
Dare Bioscience Inc
Quarterly report
10 Nov 22
4:03pm
8-K
DARE
Dare Bioscience Inc
9 Nov 22
Results of Operations and Financial Condition
5:41pm
8-K
DARE
Dare Bioscience Inc
3 Nov 22
Regulation FD Disclosure
9:15am
8-K
DARE
Dare Bioscience Inc
17 Oct 22
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
8:05am
8-K
DARE
Dare Bioscience Inc
11 Oct 22
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product
9:00am
8-K
DARE
Dare Bioscience Inc
9 Sep 22
Other Events
5:44pm